News articles about Co-Diagnostics (NASDAQ:CODX) have been trending somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Co-Diagnostics earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.9576459539526 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Co-Diagnostics (NASDAQ CODX) traded down $0.32 on Friday, reaching $4.40. Co-Diagnostics has a 52-week low of $3.50 and a 52-week high of $6.85.

COPYRIGHT VIOLATION WARNING: “Co-Diagnostics (CODX) Getting Somewhat Favorable Press Coverage, Study Shows” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.watchlistnews.com/co-diagnostics-codx-getting-somewhat-favorable-press-coverage-study-shows/1756137.html.

About Co-Diagnostics

Co-Diagnostics, Inc is a molecular diagnostics company. The Company is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid.

Insider Buying and Selling by Quarter for Co-Diagnostics (NASDAQ:CODX)

Receive News & Ratings for Co-Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.